EA017668B1 - Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов - Google Patents

Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов Download PDF

Info

Publication number
EA017668B1
EA017668B1 EA201070762A EA201070762A EA017668B1 EA 017668 B1 EA017668 B1 EA 017668B1 EA 201070762 A EA201070762 A EA 201070762A EA 201070762 A EA201070762 A EA 201070762A EA 017668 B1 EA017668 B1 EA 017668B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
mol
formula
hours
dibenzo
Prior art date
Application number
EA201070762A
Other languages
English (en)
Russian (ru)
Other versions
EA201070762A1 (ru
Inventor
Константинос Гавардинас
Прабхакар Кондаджи Джадхав
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA017668(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201070762A1 publication Critical patent/EA201070762A1/ru
Publication of EA017668B1 publication Critical patent/EA017668B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201070762A 2007-12-19 2008-12-09 Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов EA017668B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19
PCT/US2008/085997 WO2009085584A1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Publications (2)

Publication Number Publication Date
EA201070762A1 EA201070762A1 (ru) 2010-12-30
EA017668B1 true EA017668B1 (ru) 2013-02-28

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070762A EA017668B1 (ru) 2007-12-19 2008-12-09 Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов

Country Status (33)

Country Link
US (1) US7994164B2 (https=)
EP (2) EP2235007B1 (https=)
JP (1) JP5562866B2 (https=)
KR (1) KR101254382B1 (https=)
CN (1) CN101903377B (https=)
AR (1) AR069554A1 (https=)
AU (1) AU2008343524B2 (https=)
BR (1) BRPI0820805A2 (https=)
CA (1) CA2710409C (https=)
CL (1) CL2008003600A1 (https=)
CO (1) CO6300953A2 (https=)
DK (1) DK2235007T3 (https=)
DO (1) DOP2010000185A (https=)
EA (1) EA017668B1 (https=)
EC (2) ECSP10010266A (https=)
ES (2) ES2459318T3 (https=)
GT (1) GT201000179A (https=)
HR (1) HRP20120916T1 (https=)
IL (1) IL206353A (https=)
MA (1) MA31910B1 (https=)
MX (1) MX2010006911A (https=)
MY (1) MY150474A (https=)
NZ (1) NZ586300A (https=)
PE (1) PE20091057A1 (https=)
PL (1) PL2235007T3 (https=)
PT (1) PT2235007E (https=)
RS (1) RS52594B (https=)
SI (1) SI2235007T1 (https=)
TN (1) TN2010000292A1 (https=)
TW (1) TWI431010B (https=)
UA (1) UA100131C2 (https=)
WO (1) WO2009085584A1 (https=)
ZA (1) ZA201004257B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242140B2 (en) 2007-08-03 2012-08-14 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
AU2010222902B2 (en) * 2009-03-12 2013-04-18 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
EP2977084B1 (en) 2010-05-10 2017-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
JP6180930B2 (ja) 2010-06-16 2017-08-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 創傷治癒過程における再上皮化を刺激するための方法及び組成物
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
AU2014261070A1 (en) 2013-05-02 2015-10-29 Pfizer Inc. Imidazo-triazine derivatives as PDE10 inhibitors
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
MX367404B (es) 2014-06-30 2019-08-20 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
US20170246166A1 (en) * 2014-11-21 2017-08-31 Eli Lilly And Company 1,2-benzothiazole compounds for the treatment of kidney disorders
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
RU2725153C1 (ru) * 2016-09-24 2020-06-30 Кбп Биосаенсес Ко., Лтд Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение
JP7697961B2 (ja) 2020-03-11 2025-06-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 対象が中心性漿液性脈絡網膜症を有するか、または有する危険性があるかどうかを決定する方法。
US20240366632A1 (en) 2021-08-31 2024-11-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of ocular rosacea

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345747A2 (en) * 1988-06-09 1989-12-13 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
DE3730258A1 (de) * 1986-09-10 1988-04-07 Canon Kk Elektrophotographisches lichtempfindliches aufzeichnungsmaterial, 5h-dibenzo(a,d)cycloheptanylidenderivat, 5h-dibenzo(a,d)cycloheptenylidenderivat und verfahren zu ihrer herstellung
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
AR014195A1 (es) 1997-12-29 2001-02-07 Ortho Mcneil Pharm Inc Compuestos de trifenilpropanamida utiles para el tratamiento de procesos inflamatorios, composiciones anti-inflamatorias que los comprenden, ymetodos para prepararlos
US7056911B1 (en) 1999-01-26 2006-06-06 Dana-Farber Cancer Institute Dibenz[B,F]azepine compounds, pharmaceutical compositions comprising same and methods of use thereof
NZ596484A (en) * 2001-11-21 2013-05-31 Millennium Pharm Inc Chemokine receptor antagonists and methods of use thereof
US7482344B2 (en) * 2003-12-19 2009-01-27 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
CN1918151A (zh) * 2003-12-19 2007-02-21 伊莱利利公司 三环甾类激素核受体调节剂
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
RU2007107177A (ru) 2004-07-28 2008-09-10 Айрм Ллк (Bm) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
CA2585797C (en) 2004-11-10 2015-01-06 Incyte Corporation Lactam compounds and their use as pharmaceuticals
SI2089367T1 (sl) 2006-10-31 2012-02-29 Pfizer Prod Inc Spojine pirazolina kot antagonisti mineralokortikoidnih receptorjev
JP2010522732A (ja) 2007-03-29 2010-07-08 ナームローゼ・フエンノートチヤツプ・オルガノン 鉱質コルチコイド受容体アンタゴニスト
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
AU2009206733A1 (en) 2008-01-25 2009-07-30 Arena Pharmaceuticals, Inc. Dihydro- 1H- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as S1P1 agonists
AU2010222902B2 (en) 2009-03-12 2013-04-18 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345747A2 (en) * 1988-06-09 1989-12-13 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Also Published As

Publication number Publication date
CO6300953A2 (es) 2011-07-21
HK1144284A1 (en) 2011-02-11
GT201000179A (es) 2012-04-16
IL206353A (en) 2014-06-30
NZ586300A (en) 2012-06-29
EP2235007A1 (en) 2010-10-06
TW200930721A (en) 2009-07-16
ECSP12012048A (es) 2012-08-31
KR20100082866A (ko) 2010-07-20
PT2235007E (pt) 2013-01-22
CL2008003600A1 (es) 2010-02-19
RS52594B (sr) 2013-04-30
AR069554A1 (es) 2010-02-03
CN101903377A (zh) 2010-12-01
JP2011507868A (ja) 2011-03-10
ZA201004257B (en) 2011-11-30
CN101903377B (zh) 2014-07-09
ES2396605T3 (es) 2013-02-22
AU2008343524B2 (en) 2012-03-08
CA2710409A1 (en) 2009-07-09
MA31910B1 (fr) 2010-12-01
DOP2010000185A (es) 2010-09-15
EP2537845A1 (en) 2012-12-26
PL2235007T3 (pl) 2013-03-29
TWI431010B (zh) 2014-03-21
EP2537845B1 (en) 2014-03-19
SI2235007T1 (sl) 2013-01-31
ECSP10010266A (es) 2010-07-30
IL206353A0 (en) 2010-12-30
AU2008343524A1 (en) 2009-07-09
BRPI0820805A2 (pt) 2015-06-16
JP5562866B2 (ja) 2014-07-30
ES2459318T3 (es) 2014-05-09
WO2009085584A1 (en) 2009-07-09
UA100131C2 (uk) 2012-11-26
US7994164B2 (en) 2011-08-09
MY150474A (en) 2014-01-30
CA2710409C (en) 2012-11-06
EP2235007B1 (en) 2012-10-31
HRP20120916T1 (hr) 2012-12-31
DK2235007T3 (da) 2012-12-17
MX2010006911A (es) 2010-10-05
EA201070762A1 (ru) 2010-12-30
KR101254382B1 (ko) 2013-04-15
TN2010000292A1 (en) 2011-11-11
US20090163472A1 (en) 2009-06-25
PE20091057A1 (es) 2009-07-20

Similar Documents

Publication Publication Date Title
EA017668B1 (ru) Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов
AU2014242908B2 (en) Novel N-acyl-(3-substituted)-(8-methyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor-mediated disorders
RS59445B1 (sr) Derivat 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izohinolina koristan u tretmanu raka
EP4647433A1 (en) Shp2 inhibitor and uses thereof
TW201716405A (zh) 蕈毒鹼ｍ２受體之正向異位調節劑
BR112020026653A2 (pt) Compostos heterocíclicos como inibidores de trk
TW202400608A (zh) 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
CN111479813A (zh) 作为加压素v1a受体拮抗剂的三唑并苯并吖庚因
EA029311B1 (ru) Hантагонисты, имеющие феноксипиперидиновое ядро в структуре, и их применение для лечения и/или профилактики состояний, опосредуемых hрецепторами
CN109689656B (zh) 7-取代的1-芳基二氮杂萘-3-羧酰胺及其用途
TW202417458A (zh) 調節her2的化合物及方法
TW202204343A (zh) 經取代之３－苯氧基氮雜環丁烷－１－基－吡
US20250177539A1 (en) Er degraders and uses thereof
HK1144284B (en) 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists
WO2025122809A1 (en) M4 positive allosteric modulators
WO2026039512A1 (en) Kras inhibitors
TW202430523A (zh) pan-KRAS降解劑及其製備方法與應用

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KG MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ TJ RU